↓ Skip to main content

Dove Medical Press

From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting

Overview of attention for article published in Lung Cancer: Targets and Therapy, June 2023
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#35 of 135)
  • Good Attention Score compared to outputs of the same age (69th percentile)

Mentioned by

twitter
5 X users

Readers on

mendeley
4 Mendeley
Title
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Published in
Lung Cancer: Targets and Therapy, June 2023
DOI 10.2147/lctt.s413091
Pubmed ID
Authors

Alexandria T M Lee, Saihong Ignatius Ou

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 25%
Student > Doctoral Student 1 25%
Unknown 2 50%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 50%
Immunology and Microbiology 1 25%
Unknown 1 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2023.
All research outputs
#7,475,274
of 26,314,361 outputs
Outputs from Lung Cancer: Targets and Therapy
#35
of 135 outputs
Outputs of similar age
#122,429
of 399,336 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#2
of 4 outputs
Altmetric has tracked 26,314,361 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 135 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,336 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.